Adenosine Triphosphate (ATP) Assays Market Report 2025

The adenosine triphosphate (ATP) assays market size has grown rapidly in recent years. It will grow from $1.99 billion in 2024 to $2.2 billion in 2025 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to biomedical research advancements, drug discovery and development, rise in adoption in clinical diagnostics, environmental monitoring requirements, increased focus on cell-based assays.

The adenosine triphosphate (ATP) assays market size is expected to see rapid growth in the next few years. It will grow to $3.46 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to continued growth in biopharmaceutical industry, expansion of personalized medicine approaches, increased emphasis on food and beverage safety, technological innovations in assay platforms, growing application in industrial processes. Major trends in the forecast period include advancements in ATP detection technologies, rising demand for high-throughput screening, integration in clinical diagnostics, emphasis on food and beverage safety testing, application in sports and performance monitoring.

The rising incidence of cancer, chronic diseases, and infectious diseases is projected to drive the growth of the adenosine triphosphate (ATP) assay market in the future. Cancer is marked by uncontrolled cell growth that can invade and damage nearby tissues and may spread to other parts of the body. Chronic diseases are stable conditions that generally develop slowly and persist over a long period. Infectious diseases are caused by pathogenic microorganisms that can be transmitted from one person to another, including bacteria, viruses, fungi, or parasites. ATP assays serve as an important diagnostic tool for these diseases by evaluating cellular viability, detecting microbial contamination, assessing treatment effectiveness, and monitoring metabolic and mitochondrial dysfunction. For example, in February 2024, the World Health Organization, a United Nations agency based in Switzerland, projected that over 35 million new cancer cases will occur by 2050, representing a 77% increase from an estimated 20 million cases in 2022. Additionally, in 2021, the International Diabetes Federation, a Belgium-based organization focused on the diabetic community, reported that approximately 537 million adults have diabetes, with that number expected to rise to 783 million by 2045. Therefore, the growing prevalence of cancer, chronic, and infectious diseases is driving the ATP assay market.

The growing demand for personalized treatment approaches is expected to fuel the expansion of the adenosine triphosphate (ATP) assays market. Personalized treatments involve utilizing knowledge about an individual's unique genetic or protein makeup to prevent, detect, or treat diseases effectively. In the context of infectious disease management, ATP assays play a crucial role by assessing the efficacy of antimicrobial agents against specific pathogens, aiding in the selection of personalized treatment strategies. For instance, the US Food and Drug Administration (FDA) approved 12 personalized medicines in 2022, constituting around 34% of all newly approved therapeutic molecular entities, as reported by the Personalized Medicine Coalition. This surge in demand for personalized medicine underscores its pivotal role in driving the growth of the adenosine triphosphate (ATP) assays market.

The rising prevalence of chronic diseases is projected to drive the growth of the adenosine triphosphate (ATP) assays market in the coming years. Chronic diseases are illnesses that persist for three months or longer and can worsen over time. Several factors contribute to the increasing prevalence of these conditions, including an aging population, unhealthy lifestyle choices, and rapid urbanization, which lead to a rise in diseases such as diabetes, cardiovascular disease, and respiratory illnesses. ATP, the main energy carrier in cells, is measured through ATP assays to investigate disruptions in cellular energy metabolism, which are often linked to chronic diseases like diabetes, cancer, and neurodegenerative disorders. This understanding helps researchers better comprehend disease progression and develop new therapeutic strategies. For example, in February 2024, the World Health Organization, a United Nations agency based in Switzerland, projected that over 35 million new cancer cases will be diagnosed by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the ATP assays market.

The evolution of novel assays stands out as a prominent trend gaining momentum within the adenosine triphosphate (ATP) assay market. Key companies operating in this domain are introducing groundbreaking products, such as the SensiLux kit by BC Aplicaciones, a biotechnology firm based in Spain. The SensiLux kit is a unique testing solution designed for detecting microbial ATP in samples, utilizing bioluminescence for detection following sample pre-incubation. Its applications extend to areas such as food safety and contamination testing. Additionally, this offering includes ATP kits featuring advanced multi-injector automatic luminometers, proprietary control software, and future-oriented robot-based sample automation, providing customers with tailored solutions. BC Aplicaciones' programming and computer systems department have developed unique software to manage robot and luminometer operations.

Leading companies in the adenosine triphosphate (ATP) assays market are concentrating on creating advanced kinase testing platforms to offer highly sensitive assays. A kinase testing platform is a specialized system designed to assess kinase activity in biological samples, supporting drug discovery and development by providing insights into kinase function and inhibition. For example, in April 2024, Reaction Biology, a biotechnology firm based in the U.S., launched the HotSpot™ ATP-Max KinomeScreen, an advanced assay for high-throughput kinase screening that features enhanced sensitivity, allowing testing at ATP levels as low as 1 mM. This innovative platform utilizes a gold standard filter binding radiometric assay to assess kinase activity across the broadest range of kinase targets in the industry. By providing physiologically relevant data, the HotSpot ATP-Max KinomeScreen enables researchers to identify more potent and specific kinase inhibitors, thereby advancing drug discovery efforts and aiding the development of targeted therapies for various diseases, particularly cancer.

Major companies operating in the adenosine triphosphate (ATP) assays market include Merck KGaA, Thermo Fisher Scientific Inc., PerkinElmer Inc., Lonza Group, Promega Corporation, Agilent Technologies Inc., Abcam plc, Danaher Corporation, 3M Co., Geno Technology Inc., NEOGEN Corporation, Biomerieux SA, AAT Bioquest Inc., MBL International Corporation, Charm Sciences Inc., Cell Signaling Technology Inc., Cayman Chemical Company, Vazyme Biotech Co. Ltd., SignalChem Lifesciences Corporation, Kaneka Corporation, Novus Biologicals LLC, NANOGEN Biotechnologies Inc., Nacalai Tesque Inc., MoBiTec GmbH, Lumigen Inc., Jena Bioscience GmbH, Goryo Chemical Inc., Cosmo Bio Co. Ltd., BPS Bioscience Inc., BioTek Instruments Inc.

North America was the largest region in the adenosine triphosphate (ATP) assays market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adenosine triphosphate (atp) assays market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adenosine triphosphate (atp) assays market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

ATP assays, or adenosine triphosphate assays, serve as analytical procedures to determine ATP concentrations in biological materials. ATP, an energy-carrying molecule present in cells of all living organisms, extracts chemical energy from the breakdown of food molecules and utilizes it to power various cellular functions. This assay plays a crucial role in monitoring cellular energy state and function, serving as a vital tool in research, diagnostics, and drug discovery.

The primary types of ATP assays include luminometric ATP assays, enzymatic ATP assays, bioluminescence resonance energy transfer (BRET) ATP assays, cell-based ATP assays, among others. Luminometric ATP assays, specifically, leverage bioluminescence principles to measure ATP levels in samples. They are widely used in research, drug discovery, and biomedical applications for assessing cellular energy status, measuring enzymatic activity, evaluating cell viability, and screening ATP-modulating compounds. These assays consist of essential components such as consumables, accessories, and instruments utilized across diverse fields including drug discovery and development, clinical diagnostics, environmental testing, and food safety and quality assessment. Their applications extend to various end-users such as pharmaceutical and biotechnology companies, the food and beverage industry, hospitals, diagnostics laboratories, as well as academic and research institutions.

The adenosine triphosphate (ATP) assays market research report is one of a series of new reports that provides adenosine triphosphate (ATP) assays market statistics, including adenosine triphosphate (ATP) assays industry global market size, regional shares, competitors with an adenosine triphosphate (ATP) assays market share, detailed adenosine triphosphate (ATP) assays market segments, market trends and opportunities, and any further data you may need to thrive in the adenosine triphosphate (ATP) assays industry. This adenosine triphosphate (ATP) assays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The adenosine triphosphate (ATP) assays market consists of revenues earned by entities by providing testing services related to colorimetric and fluorescent assays. The market value includes the value of related goods sold by the service provider or included within the service offering. The adenosine triphosphate (ATP) assays market also includes sales of luminometer, and chemiluminescent which are used in adenosine triphosphate (ATP) assay services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.